about
Therapeutic targets: progress of their exploration and investigation of their characteristics.Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS).SVM model for virtual screening of Lck inhibitors.Consensus model for identification of novel PI3K inhibitors in large chemical library.Comparative evaluation of software for retention time alignment of gas chromatography/time-of-flight mass spectrometry-based metabonomic data.Pilot study on developing a decision support tool for guiding re-administration of chemotherapeutic agent after a serious adverse drug reactionConsensus QSAR model for identifying novel H5N1 inhibitors.Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.Clinical and demographic predictors for vitamin D deficiency in multiethnic Asian patients with chronic kidney disease.Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study.A clinical decision support tool to predict survival in cancer patients beyond 120 days after palliative chemotherapyIsorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer.Prediction of compounds with specific pharmacodynamic, pharmacokinetic or toxicological property by statistical learning methods.Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties.Social isolation, loneliness and their relationships with depressive symptoms: A population-based studyA scoring model for predicting survival following primary tumour resection in stage IV colorectal cancer patients with unresectable metastasis.Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway.Determination of the Potential of Drug Candidates to Cause Severe Skin Disorders Using Computational Modeling.QSAR and Predictors of Eye and Skin Effects.QSAR Modeling is not "Push a Button and Find a Correlation": A Case Study of Toxicity of (Benzo-)triazoles on Algae.Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.Selective agonism of human pregnane X receptor by individual ginkgolides.Prediction of torsade-causing potential of drugs by support vector machine approach.Mixed learning algorithms and features ensemble in hepatotoxicity prediction.Prediction of factor Xa inhibitors by machine learning methods.Prediction of P-glycoprotein substrates by a support vector machine approach.Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry.Effect of molecular descriptor feature selection in support vector machine classification of pharmacokinetic and toxicological properties of chemical agents.Prevalence of frailty and its association with depressive symptoms among older adults in Singapore.TRMP: a database of therapeutically relevant multiple pathways.Quantitative Structure-Pharmacokinetic Relationships for drug distribution properties by using general regression neural network.HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years.A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.Effect of selection of molecular descriptors on the prediction of blood-brain barrier penetrating and nonpenetrating agents by statistical learning methods.Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.Sex differences in associations between multimorbidity and physical function domains among community-dwelling adults in Singapore.Formulation development of transdermal dosage forms: quantitative structure-activity relationship model for predicting activities of terpenes that enhance drug penetration through human skinQSAR classification of metabolic activation of chemicals into covalently reactive species
P50
Q30354509-B1B6A26A-5A66-4B7B-9616-BEF5DD89BA3BQ33392383-886872AB-E5BC-4D97-91CA-37D303D67EF6Q33415613-B5684C80-9BA8-4C41-B138-F9624493C9A1Q33530647-8F22C33E-149A-440C-87B2-DB3722DE6A9AQ33748317-3EE3F06A-D8D0-4B70-AF5D-F05D01D86274Q33973091-82E0F8E5-6358-4642-814D-D62C0FD751D7Q34347449-700F7EA0-6D44-42F2-AA22-F8C4CBF0B8E7Q35234394-057528C2-63CA-40F6-84EC-C74E19E4F6D3Q35366654-AB8F48BC-9543-4C8C-8A55-9FE041C80B91Q35811858-0D1F57C5-75A4-405C-95E3-C7360FAC91F5Q36093188-47ADC07B-A284-4677-901A-0A18B6FD21A2Q36368271-C3F2C0F9-00CE-4ACB-8638-A09B5ABFF29DQ36448801-5FBBD2EE-26DC-419F-BAB6-23712B399862Q37018056-3BEC24EC-EBDF-42CA-8056-6DF8C3ADBB73Q38612592-F1F92382-CFCD-4619-AEB6-047F565E2DD7Q38951116-A25B961B-C2E5-4BB6-9AFB-C90B4E48A6EFQ39264944-2AB607BB-7B68-4A80-A9DB-13791C3762C5Q39523385-81444D0A-DA4D-44FA-B538-1E5F135B3341Q39535536-1E5DBADC-9AB8-4FDA-AE23-9993D17824C0Q39535548-0E8735EC-844E-4BB7-95D1-5B79CC80959CQ39540764-91873B23-F79B-4AB9-B9AF-BFB59324DDC4Q40296339-71987F89-3C1C-41E1-B930-6994F512A8B4Q40348573-3A2C0E40-A330-4343-89DA-31857E4B27B8Q44188837-4ABF6DBB-AAD1-42B6-A6FB-17ECAAC4C621Q44771784-E4594B16-FC91-487B-8E93-FB9FF1E3B412Q45372748-B0F313EB-9FBB-4429-86AC-71743F9B97C8Q45965422-7CD33379-2C9F-4C7A-92D1-FCEAFAC8BBB2Q45966716-DA71DC63-C503-4C46-95AC-7C205B0324FAQ46172959-F2C33A15-30DA-4415-9B39-4FA3F2BBE50EQ47406031-532EA470-DB9F-4589-804D-160E80A15AFFQ47552963-979F8DEB-46FA-4631-B27C-9ABFE758A367Q47835181-F0168305-1F6B-4E68-9D23-3711A0F576FFQ48971753-5B92B69B-CBF9-4B7E-9242-3C41FF865026Q50709035-5ACF2A71-0CB4-4C7D-9100-DA4219EE9A30Q51904438-00A955C7-BBCC-426E-8716-6433FD2BEDECQ51963838-CD68174D-2C35-4CA1-A7AC-0053B691818BQ53804425-F38954B8-6A9F-4121-867E-2E9AFC328564Q55003031-8DAD3372-CCB8-4502-9327-F02EAC9951FDQ80508286-2039A362-5048-4E58-8E4A-9BC2D31B6F7DQ83524784-1C8137BC-FDD5-4AF0-A51D-B1E4E05EB792
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chun Wei Yap
@ast
Chun Wei Yap
@en
Chun Wei Yap
@es
Chun Wei Yap
@nl
type
label
Chun Wei Yap
@ast
Chun Wei Yap
@en
Chun Wei Yap
@es
Chun Wei Yap
@nl
prefLabel
Chun Wei Yap
@ast
Chun Wei Yap
@en
Chun Wei Yap
@es
Chun Wei Yap
@nl
P106
P1153
8392348900
P2456
P31
P496
0000-0002-2004-3492